Last reviewed · How we verify
Intravenous iclaprim
Iclaprim is a dihydrofolate reductase (DHFR) inhibitor that disrupts bacterial folate metabolism, preventing DNA synthesis and bacterial growth.
Iclaprim is a dihydrofolate reductase (DHFR) inhibitor that disrupts bacterial folate metabolism, preventing DNA synthesis and bacterial growth. Used for Complicated skin and soft tissue infections (cSSTI), Hospital-acquired bacterial pneumonia (HABP) / Ventilator-associated bacterial pneumonia (VABP).
At a glance
| Generic name | Intravenous iclaprim |
|---|---|
| Sponsor | Arpida AG |
| Drug class | Dihydrofolate reductase inhibitor |
| Target | Dihydrofolate reductase (DHFR) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Iclaprim binds to bacterial dihydrofolate reductase with high affinity, blocking the conversion of dihydrofolate to tetrahydrofolate, which is essential for one-carbon transfer reactions and nucleotide synthesis. This mechanism is bacteriostatic and selective for bacterial DHFR over human DHFR, making it suitable for treating bacterial infections. The drug has activity against a broad spectrum of gram-positive and some gram-negative bacteria, including methicillin-resistant Staphylococcus aureus (MRSA).
Approved indications
- Complicated skin and soft tissue infections (cSSTI)
- Hospital-acquired bacterial pneumonia (HABP) / Ventilator-associated bacterial pneumonia (VABP)
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Elevated liver enzymes
- Phlebitis at infusion site
Key clinical trials
- Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-2 (PHASE3)
- Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-1 (PHASE3)
- Clinical Efficacy of Intravenous Iclaprim Versus Vancomycin in the Treatment of Hospital-Acquired, Ventilator-Associated, or Health-Care-Associated Pneumonia (PHASE2)
- Phase 3 Safety and Efficacy Study of I.V. Iclaprim v Linezolid in cSSSI (ASSIST-1) (PHASE3)
- Study of Intravenous (I.V.) Iclaprim Versus Linezolid in Complicated Skin and Skin Structure Infections [cSSSI] (ASSIST-2) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous iclaprim CI brief — competitive landscape report
- Intravenous iclaprim updates RSS · CI watch RSS
- Arpida AG portfolio CI